Vallet Sonia, Hoyle Nicholas R, Kyle Robert A, Podar Klaus, Pecherstorfer Martin
a Department of Oncology , University Hospital Krems and Karl Landsteiner University , Krems an der Donau , Austria.
b Murnau , Germany.
Leuk Lymphoma. 2018 Oct;59(10):2431-2438. doi: 10.1080/10428194.2017.1421757. Epub 2018 Jan 18.
Multiple myeloma (MM) is characterized by bone lesions arising due to unbalanced bone remodeling. Changes in the bone formation marker amino-terminal propeptide of type I collagen (PINP) and the bone resorption marker β-CrossLaps (CTX) reflect physiologic bone turnover. Whether PINP and CTX have a role in disease progression from monoclonal gammopathy of undetermined significance (MGUS) to MM is unknown. In this cross-sectional follow-up study, 241 patients with MM or MGUS were included. Serum levels of PINP and CTX were significantly higher in MM patients compared to MGUS. Moreover, increasing concentrations of PINP and CTX were observed in those MGUS patients progressing to MM, whereas PINP and CTX levels remained unchanged in MGUS patients with stable disease. In conclusion, these data indicate a potential role of PINP and CTX as biomarkers for the progression of MGUS to MM.
多发性骨髓瘤（MM）的特征是由于骨重塑失衡而产生骨病变。骨形成标志物I型胶原氨基端前肽（PINP）和骨吸收标志物β-交联C端肽（CTX）的变化反映了生理性骨转换。PINP和CTX在意义未明的单克隆丙种球蛋白病（MGUS）向MM的疾病进展中是否起作用尚不清楚。在这项横断面随访研究中，纳入了241例MM或MGUS患者。与MGUS患者相比，MM患者的血清PINP和CTX水平显著更高。此外，在进展为MM的MGUS患者中观察到PINP和CTX浓度增加，而病情稳定的MGUS患者中PINP和CTX水平保持不变。总之，这些数据表明PINP和CTX作为MGUS进展为MM的生物标志物具有潜在作用。
